Anti-EpCAM monoclonal antibody K931
Alternative Names: Anti-EpCAM monoclonal antibody - Heidelberg Pharma; K 931; WX K931Latest Information Update: 20 Nov 2017
At a glance
- Originator VU University Medical Center
- Developer Wilex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epithelial cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 May 2003 Anti-EpCAM monoclonal antibody K931 has been exclusively licensed to Wilex for the treatment of advanced solid cancers
- 15 May 2003 Preclinical development for Solid tumours in Germany (unspecified route)
- 15 May 2003 Preclinical development for Solid tumours in Netherlands (unspecified route)